ArticleCurrent neuropharmacology2014
Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.
Article in Current neuropharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- The locus coeruleus at the crossroads of inflammation and neurodegeneration in multiple sclerosis.Journal of neuroinflammation · 2026Review
- Reboxetine Treatment Reduces Hippocampal Gliosis in the P301S Tauopathy Mouse Model.ASN neuro · 2026Article
- Locus coeruleus-entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Article
- Regenerating Locus Coeruleus-Norepinephrine (LC-NE) Function: A Novel Approach for Neurodegenerative Diseases.Cell proliferation · 2025Review
- Article
- Microstructural associations between locus coeruleus, cortical, and subcortical regions are modulated by astrocyte reactivity: a 7T MRI adult lifespan study.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Chemogenetic activation of locus coeruleus neurons ameliorates the severity of multiple sclerosis.Journal of neuroinflammation · 2023Article
- Multisensory Stimulation Reverses Memory Impairment in AdrβInternational journal of molecular sciences · 2023Article
- The Contribution of the Locus Coeruleus-Noradrenaline System Degeneration during the Progression of Alzheimer's Disease.Biology · 2022Review
- What is the protective effect of preischemic kisspeptin-10 administration against ischemia/reperfusion injury of striatum on mice?Turkish journal of medical sciences · 2022Article
- Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target.International journal of molecular sciences · 2022Review
- Sublingual AKBA Exerts Antidepressant Effects in the Aβ-Treated Mouse Model.Biomolecules · 2021Article
- The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease.Acta neuropathologica · 2021Review
- Locus coeruleus MRI contrast is associated with cortical thickness in older adults.Neurobiology of aging · 2021Article
- Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.Molecular psychiatry · 2021Article
- Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge-A New Hypothesis With Potential Implications for Neurodegenerative Diseases.Frontiers in neurology · 2020Article
- Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer's Disease: Role of CCL2.Molecular neurobiology · 2019Article
- Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson's disease model.Behavioural brain research · 2019Article
- The Astrocytic cAMP Pathway in Health and Disease.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been known for many years that the endogenous neurotransmitter noradrenaline (NA) exerts anti-inflammatory and neuroprotective effects both in vitro and in vivo. In many cases the site of action of NA are beta-adrenergic receptors (βARs), causing an increase in intracellular levels of cAMP which initiates a broad cascade of events including suppression of inflammatory transcription factor activities, alterations in nuclear localization of proteins, and induction of patterns of gene expression mediated through activity of the CREB transcription factor. These changes lead not only to reduced inflammatory events, but also contribute to neuroprotective actions of NA by increasing expression of neurotrophic substances including BDNF, GDNF, and NGF. These properties have prompted studies to determine if treatments with drugs to raise CNS NA levels could provide benefit in various neurological conditions and diseases having an inflammatory component. Moreover, increasing evidence shows that disruptions in endogenous NA levels occurs in several diseases and conditions including Alzheimer's disease (AD), Parkinson's disease (PD), Down's syndrome, posttraumatic stress disorder (PTSD), and multiple sclerosis (MS), suggesting that damage to NA producing neurons is a common factor that contributes to the initiation or progression of neuropathology. Methods to increase NA levels, or to reduce damage to noradrenergic neurons, therefore represent potential preventative as well as therapeutic approaches to disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.